Combination of CpG Oligodeoxynucleotide and Anti-4-1BB Antibody in the Treatment of Multiple Hepatocellular Carcinoma in Mice

References

• Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res. 2013;19(24):6678–6685. doi:10.1158/1078-0432.CCR-13-172124030702
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Kim A, Ronnekleivkelly SM, et al. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85. doi:10.1016/j.suronc.2016.03.00227312032
   PubMed Web of Science ®Google Scholar
• Gomes MA, Priolli DG, Tralhao JG, et al. Carcinoma hepatocelular: epidemiologia, biologia, diagnóstico e terapias. Rev Assoc Med Bras. 2013;59(5):514–524. doi:10.1016/j.ramb.2013.03.00524041910
   PubMed Web of Science ®Google Scholar
• Sherman M. Hepatocellular carcinoma. Gastroenterologist. 2016;20(4):703–720.
   Google Scholar
• Molinari M, Coutere SD, Krahn M, et al. Patients’ preferences and trade-offs for the treatment of early stage hepatocellular carcinoma. J Surg Res. 2014;189(1):57–67. doi:10.1016/j.jss.2014.02.01524650457
   PubMed Web of Science ®Google Scholar
• Ye L, Zhang Q, Cheng Y, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1 + regulatory B cell expansion. J Immunother Cancer. 2018;6(1):1–15. doi:10.1186/s40425-018-0451-629298730
   PubMedGoogle Scholar
• Lv Y, Zhao Y, Wang X, et al. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway. J Immunother Cancer. 2019;7(1):1–15. doi:10.1186/s40425-019-0530-330612589
   PubMedGoogle Scholar
• Capasso A, Lang J, Pitts TM, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019;7(1):37. doi:10.1186/s40425-019-0518-z30736857
   PubMedGoogle Scholar
• Sommariva M, Noci VL, Storti C, et al. Activation of NK cell cytotoxicity by aerosolized CpG-ODN/Poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages. Cell Immunol. 2017;313:52–58. doi:10.1016/j.cellimm.2017.01.00428089340
   PubMed Web of Science ®Google Scholar
• Lai C, Duan S, Ye F, et al. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Theranostics. 2018;8(6):1723–1739. doi:10.7150/thno.2205629556352
   PubMed Web of Science ®Google Scholar
• Li J, Li J, Aipire A, et al. The combination of Pleurotus ferulae water extract and CpG-ODN enhances the immune responses and antitumor efficacy of HPV peptides pulsed dendritic cell-based vaccine. Vaccine. 2016;34(31):3568–3575. doi:10.1016/j.vaccine.2016.05.02227211038
   PubMed Web of Science ®Google Scholar
• Ignacio RMC, Kim CS, Kim YD, et al. Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma murine model. Cytokine. 2015;76(2):131–137. doi:10.1016/j.cyto.2015.06.00226082022
   PubMed Web of Science ®Google Scholar
• Liang S, Hu J, Xie Y, et al. A polyethylenimine-modified carboxyl-poly(styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-β receptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice. Int J Nanomedicine. 2016;11:6753–6762. doi:10.2147/IJN.S12204728008250
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yuan RF, Li XH, et al. Clinical effects of CpG-based treatment on the efficacy of hepatocellular carcinoma by skewing polarization toward M1 macrophage from M2. Cancer Biother Radiopharm. 2017;32(6):215–219. doi:10.1089/cbr.2017.224028820636
   PubMed Web of Science ®Google Scholar
• Yang X, Lai C, Liu A, et al. Anti-tumor activity of mannose-CpG-oligodeoxynucleotides-conjugated and hepatoma lysate-loaded nanoliposomes for targeting dendritic cells in vivo. J Biomed Nanotechnol. 2019;15(5):1018–1032. doi:10.1166/jbn.2019.275530890232
   PubMed Web of Science ®Google Scholar
• Compte M, Harwood SL, Munoz IG, et al. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nat Commun. 2018;9(1):4809. doi:10.1038/s41467-018-07195-w30442944
   PubMedGoogle Scholar
• Menk AV, Scharping NE, Rivadeneira DB, et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 2018;215(4):1091–1100. doi:10.1084/jem.2017106829511066
   PubMed Web of Science ®Google Scholar
• Chester C, Sanmamed MF, Wang J, et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2017;131(1):49–57. doi:10.1182/blood-2017-06-74104129118009
   PubMed Web of Science ®Google Scholar
• Buchan SL, Dou L, Remer M, et al. Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity. 2018;49(5):958–970. doi:10.1016/j.immuni.2018.09.01430446386
   PubMed Web of Science ®Google Scholar
• Misumi T, Tanabe K, Fujikuni N, et al. Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer. PLoS One. 2018;13(10):e0204880. doi:10.1371/journal.pone.020488030321186
   PubMed Web of Science ®Google Scholar
• Fromm G, De Silva S, Giffin L, et al. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) combination vaccine improves T-cell priming and enhances immunity, memory, and tumor elimination. Cancer Immunol Res. 2016;4(9):766–778. doi:10.1158/2326-6066.CIR-15-022827364122
   PubMed Web of Science ®Google Scholar
• Pan P, Gu P, Li Q, et al. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol. 2004;172(8):4779–4789. doi:10.4049/jimmunol.172.8.477915067054
   PubMed Web of Science ®Google Scholar
• Sfondrini L, Sommariva M, Tortoreto M, et al. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Int J Cancer. 2013;133(2):383–393. doi:10.1002/ijc.2802823319306
   PubMed Web of Science ®Google Scholar
• Horsman MR, Vaupel P. Pathophysiological basis for the formation of the tumor microenvironment. Front Oncol. 2016;6:66. doi:10.3389/fonc.2016.0006627148472
   PubMed Web of Science ®Google Scholar
• Ventola CL. Cancer immunotherapy, Part 3: challenges and future trends. P T. 2017;42(8):514.28781505
   PubMedGoogle Scholar
• Li X, Shao C, Shi Y, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11(1):31. doi:10.1186/s13045-018-0578-429482595
   PubMedGoogle Scholar
• Lussier DM, Woolf EC, Johnson JL, et al. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer. 2016;16(1):310. doi:10.1186/s12885-016-2337-727178315
   PubMedGoogle Scholar
• Nouri N, Garbe C. Intralesional immunotherapy as a strategy to treat melanoma. Expert Opin Biol Ther. 2016;16(5):619–626. doi:10.1517/14712598.2016.115716126898656
   PubMed Web of Science ®Google Scholar
• Ioannou XP, Gomis S, Hecker R, et al. Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits. Vaccine. 2003;21(27):4368–4372. doi:10.1016/S0264-410X(03)00437-714505919
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sznol M, et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010;37(5):508–516. doi:10.1053/j.seminoncol.2010.09.00821074066
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061. doi:10.1126/science.107949012522256
   PubMed Web of Science ®Google Scholar